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BACKGROUND 20
21
The introduction of a live attenuated Rotavirus vaccine (Rotarix®, GlaxoSmithKline Biologicals), to 22 the UK's child immunisation schedule in July 2013 has resulted in significant improvements in 23 morbidity and healthcare usage by preventing rotavirus acute gastroenteritis (RAGE). In the UK 93% 24 of eligible children complete their vaccination course with evidence of substantial herd protection 25 (1) . 26
Although the main symptoms of rotavirus infection are gastrointestinal, it is also linked to central 27 nervous system (CNS) pathology. Studies from the United States (US) reported that up to 7% of 28 infected children experience convulsions (2). These may be febrile convulsions secondary to the 29 pyrexia frequently associated with rotavirus, or alternatively a direct effect of infection as rotavirus 30 has been detected both in blood (3) and cerebrospinal fluid (4). Other putative mechanisms are 31 indirect neurotoxicity, mediated through NSP4 enterotoxin (5) or nitric oxide (6). With rotavirus 32 infection frequently gastro-intestinally asymptomatic (7), it may potentially be an under-recognised 33 cause of CNS morbidity. 34
In the US, Payne et al (8) performed a large retrospective cohort analysis of over 250,000 children 35 from the CDC Vaccine Safety Datalink database and found an 18-21% risk reduction in rates of 36 Emergency Department (ED) attendance or admission to hospital with childhood seizures in the year 37 after rotavirus vaccination. A second study from the US using an insurance claim database of 1.8 38 million children showed a 24% risk reduction of seizure hospitalisations persisting up to five years 39 after vaccination (9). Both studies used Cox regression to analyse time to event, despite this 40 technique assuming that the factors investigated have a constant impact on the hazard -or risk -41 over time (10). In Australia, Sheridan (11) used the screening method to compare the vaccination 42 status of 2211 children attending the ED with febrile seizures to the general population and found 43 vaccine effectiveness of 35-38% for preventing presentation to the ED in the two years after 44 vaccination. However ecological studies examining population-level benefit have found more 45 variable strengths of association against seizure hospitalisation, ranging from 1 -8% in an 46 interrupted time series analysis (ITS) in the USA (12), a non-significant 16 -34% trend in an 47 uncontrolled before/after study design in North West Spain (13), to no association at all in South 48
East Spain (14). 49
With such striking but inconsistent findings on one of the conditions most feared by parents (15), 50 we felt it important to assess if the same effect could be detected in the UK. We chose to examine have established a protective vaccine association in this age group, with some the largest impact in 65 these infants (13), likely because they have the highest burden of rotavirus infection. As an analysis 66 of non-identifiable routinely collected data, following HRA guidance (17), our study did not require 67 ethical review. 68
Data analysis 69
We fitted separate regression models for febrile and afebrile seizure counts; offset for English 70 population changes using Office for National Statistics (ONS) mid-year estimates. Due to the 71 immediate nature of vaccine introduction we tested for both a step and slope change in the rate of 72 admissions before and after vaccine introduction. Age and year of admission were included in the 73 model as predictor co-variates. To avoid autocorrelation we analysed by whole year periods and 74 assessed this using the Durbin-Watson test. In our secondary analyses we fitted separate models by 75 age group to assess the effects of vaccination on both afebrile and febrile seizures, both of which 76 could both be aetiologically relevant to rotavirus but have different age admission patterns. We also 77 performed a further separate sub-analysis examining annual admissions in March -the height of 78 Rotavirus season in England. As model residuals showed evidence of over-dispersion using the 79 Poisson distribution, in the final analysis we used the negative binomial distribution. We corrected 80 for multiple testing using the Holm method. Data analysis was performed using R 3.4.1.(19) 81
RESULTS 82
During the 10-year study, the English population under 3 years old encompassed approximately 20 83 million children (ONS). We identified 125,096 and 113,775 first-time admissions with afebrile and 84 febrile seizures, respectively, across all hospitals in England, resulting in overall mean incidence rates 85 of 623 and 568 /100,000 population. Rates of completed vaccine use in English eligible children 86 remain consistently high, averaging 90% since introduction (18). England's birth rate was also stable, 87 with a mean of 672,216 ± SD 13,166 children born per year (ONS). 88
The absolute numbers and rates of admission with non-febrile seizures remained broadly 89 comparable ( Table 1) , even when analysis was restricted to different age groups (Figure 1 ). There 90 was a decreasing trend in admissions with febrile convulsions, pre-dating the introduction of the 91 rotavirus vaccine (Table 1 ). This trend is particularly well demonstrated for those aged 1-2 years 92 ( Figure 1 ), in whom we see the peak of presentation with febrile convulsions. 93 Our primary outcome model did not detect a statistically significant reduction in annual admissions 94 of under 3 year olds with either febrile, afebrile or all seizures in association with vaccine 95 introduction and use (Table 2 ). Sub-analysis by age groups failed to show any significant relationship 96 with vaccine use when adjusted for multiple testing in those aged 0-2 years old. A p value of 0.01 97 (Table 2) was noted in those aged 2-3 when examining annual all-cause childhood seizure admissions 98 in association with rotavirus vaccination. However in this subgroup, our ITS analysis is limited to only 99 one year of post-vaccine data to compare to 9 years of pre-vaccine data and may not be truly 100 significant. When the model was restricted to rates of admission in March, the peak of the rotavirus 101 season in England, a reported p value of 0.01 was noted in relation to vaccine use and reduction of 102 febrile seizures in those aged 2-3 years (Figure 2) , alongside a p value of 0.002 in this age group for 103 all-cause seizures ( Table 2) . As noted before, this age group is limited to only one year of post 104 vaccine data and though corrected for multiple testing -is an analysis of a subset (by age group) in a 105 subset (March only admissions). A planned secondary analysis looking at the primary research 106 question but analysing all admissions with seizures, as opposed to first admission, had the same 107 findings (data not shown). 108
CONCLUSIONS 109
Our study assessed the age-specific incidence rates of paediatric admissions with febrile and afebrile 110 seizures for all English NHS Trusts across a 10-year period. Using ITS analysis, we did not detect a 111 reduction in the rate of seizure admissions of <3 year olds associated with the mid-study 112 introduction of rotavirus vaccine. We observed a reduction in the number of admissions with febrile 113 seizures that pre-dated vaccine introduction and is likely to be due to evolving patterns of admission 114 from pressures on hospital bed availability. This is consistent with the study from South East Spain 115 where rotavirus vaccination initially appeared negatively correlated with childhood seizure 116 admissions, and all cause hospitalisation but accounting for confounders such as total hospitalisation 117 rate there was no vaccine specific effect on seizures (14). They too attributed the decreasing trend in 118 seizure hospitalisations to changes in admission policies from financial constraints following the 119 economic crisis. When examining admissions in the peak of rotavirus season, we found a potential 120 signal suggesting reduction in febrile seizures in children aged 2-3 years old. However with only one 121
year of post-vaccine data in this age group we feel this is statistical artefact. The peak age of febrile 122 seizures is 18 months and in this age cohort we did not detect any effect despite younger children 123 with seizure being more likely to be admitted. 124
The strength of our study is its robust ecological size, comparing trends over a decade across the 125 whole of the English paediatric population. Although an alternative study design, we analysed 80 to 126 100-fold more seizures requiring medical attention than the aforementioned three cohort studies (8-127 9, 14). These found varying strengths of direct protective association, with the lowest reported as a 128 20% risk reduction in risk of seizures. Despite the inherent flaws of an ecological study design, if 129 such a significant effect existed in England we believe our much larger study would have detected a 130 signal, given that our vaccine uptake is also higher. Thus we argue that this is an important negative 131 finding; if a protective association of the monovalent vaccine cannot be detected at such this 132 population level then the effect is unlikely to be clinically, or economically, significant. 133
134
A major limitation of our study is that our data source only recorded paediatric hospital admissions 135 and did not capture ED attendances. We were not able to examine whether vaccine effect can be 136 found in presentations of convulsions to the ED where more minor attendances may be discharged 137 after a period of observation. Current national emergency datasets in England do not consistently 138 record discharge diagnoses and so do not allow the same analyses. Reassuringly both of the cohort 139 studies (8,11) that examined this still reported a significant finding for their sub-analyses of only 140 admitted patients. 141
As the HES dataset is centrally anonymised, a further limitation of our study is that we were unable 142 to independently assess the accuracy of ICD-10 coding. However a seizure is a significant clinical 143 event and is likely to be well recorded. Given that hospitals are paid based on these records they are 144 financially incentivised to maintain the accuracy of them, as such they are the standard inpatient 145 dataset for the UK. 
